We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Novel Coronavirus Could Be Targeting Kidneys, Suggests New Data

By LabMedica International staff writers
Posted on 19 Mar 2020
New data on the coronavirus disease has revealed that kidney involvement appears to be frequent in people who have tested positive and developed symptoms. More...
Proteinuria (and/or blood in urine) often occurs at the beginning or during the infection, with a few patients even developing acute kidney injury (AKI), thus indicating that COVID-19 also attacks the kidneys. Given the involvement of kidneys during coronavirus infection, patients should also be monitored after the disease.

This is based on two studies which showed a high rate of renal abnormalities in corona-positive patients. In the first study, after being admitted to the hospital, 34% of the 59 patients developed massively elevated levels of albumin in urine (proteinuria), a symptom of kidney damage, while 63% of the study patients developed proteinuria while in hospital, and many of them also had blood loss in their urine (hematuria). Kidney function was impaired in 27% of the study population and in 66% of the patients who died from the coronavirus infection. These findings were supported by a second study involving 710 hospitalized patients. Upon admission, 44% of the patients had hematuria and proteinuria (26.7% had only hematuria), while kidney function decreased in nearly 15% of the patients.

“This shows that COVID-19 also attacks the kidneys, not just the lungs,” said Professor Carmine Zoccali, President of the ERA-EDTA (Parma, Italy). “Although the percentage of overall group of COVID-19 infected patients that develop AKI during infection is rather low (about 3-9%), we have to keep in mind that these patients obviously have a poor prognosis. These patients should be treated in accordance with best-practice guidelines in nephrology, which includes supportive management as well as dialysis.”

Continuous Renal Replacement Therapy (CRRT) may also be effective in treating patients with COVID-19 and sepsis syndrome (regardless of their kidney function). On the other hand, patients with chronic kidney disease and especially dialysis patients are at high risk because comorbidities increase the risk of dying from COVID-19.

“Many have already recovered from the disease. AKI patients should be seen regularly by nephrologists, because the risk of these patients developing chronic kidney disease is high. But given the involvement of kidneys during coronavirus infection, we should also monitor those patients who did not develop AKI, but proteinuria and/or hematuria. Otherwise there is a risk that the corona epidemic will be followed by an epidemic of chronic and end-stage kidney disease,” added Zoccali.

Related Links:
ERA-EDTA


Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.